Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05784441
PHASE1

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Sponsor: Janssen Research & Development, LLC

View on ClinicalTrials.gov

Summary

The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?

Official title: A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

21

Start Date

2023-11-06

Completion Date

2040-01-03

Last Updated

2026-03-13

Healthy Volunteers

No

Interventions

DRUG

JNJ-90009530

JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20

Locations (15)

University of Iowa Hospital

Iowa City, Iowa, United States

University of Kentucky

Lexington, Kentucky, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Rutgers University

New Brunswick, New Jersey, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

MD Anderson Cancer Center

Houston, Texas, United States

Royal Prince Alfred Hospital

Camperdown, Australia

Monash Medical Centre

Clayton, Australia

Austin Hospital

Heidelberg, Australia

Royal Brisbane and Women's Hospital

Herston, Australia

Westmead Hospital

Westmead, Australia

Hadassah Medical Center

Jerusalem, Israel

Sheba Medical Center

Ramat Gan, Israel

University College London Hospitals

London, United Kingdom